National and Kapodistrian University of Athens
Μοριακή μελέτη για την ανακάλυψη βιοδεικτών και θεραπευτικών στόχων στον καρκίνο της ουροδόχου κύστης
Abstract
dc:descriptionDiagnosis, treatment and follow-up of bladder cancer is a complex global health problem. The role of cytology in the diagnosis and monitoring of bladder cancer is crucial. The revised Paris System for Reporting Urinary Cytology (TPS) presented clearly defined morphologic criteria, emphasizing in the most clinically relevant diagnosis of high-grade urothelial carcinoma, reducing uncertain diagnoses. In our study, we evaluated the risk of malignancy (ROM) for each TPS category by studying prospectively 110 patients who underwent transurethral removal of bladder tumor in our clinic. The diagnostic accuracy of urine cytology proved to be very high for the diagnosis of high-grade urothelial carcinoma, supporting the fundamental role of cytology in urinary oncology. In an effort to enhance the ability to predict bladder cancer recurrence, we compiled a discovery meta-cohort of 1135 bladder cancer microarray transcriptomes and addressed the disease as a molecular continuum of alterations. Using the stage as a checkpoint variable that reflects the cumulative processes of tumor progression, we investigated how molecular processes and gene expression levels change. Based on the hypothesis that the expression levels of the most optimal prognostic biomarkers should follow a monotonal trend with higher disease stage, we propose an eight-gene signature, capable of stratifying patients into low- and high-risk for bladder cancer recurrence probability. Finally, by selecting one of the 8 genes of the gene signature, ZFP2, which is the less studied in the literature, we created a preliminary cohort of 14patients who underwent transurethral removal of bladder tumor in 1st Urology Department of the University of Athens. In these samples we measured ZFP2 gene expression by PT-PCR analysis. Data analysis confirmed our observations and showed that ZFP2 gene expression levels are upregulated in those patients who remain relapse-free. Further validation of the use of ZFP2 in clinical trials is required before clinical implementation in the follow-up of bladder cancer.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2023
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Moulavasilis, Napoleon
- Μουλαβασίλης, Ναπολέων
Subjects
dc:subject × 18- Καρκίνος
- Ουροδόχος κύστη
- Βιοδείκτης
- Κυτταρολογία
- Cancer
- Bladder
- Biomarker
- Cytology
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Ουρολογία
- Άλλες Ιατρικές Επιστήμες
- Ιατρική έρευνα και Πειραματική ιατρική
- Clinical Medicine
- Medical and Health Sciences
- Urology
- Other Medical Sciences
- Research and Experimental medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/55492